Official ESCRS | European Society of Cataract & Refractive Surgeons

 

Posters

Search Title by author or title

Challenges of exfoliation syndrome (XFS) management

Poster Details

First Author: S.Jandroković CROATIA

Co Author(s):    S. Popović Suić   I. Škegro   S. Masnec              

Abstract Details

Purpose:

The objective of the study was to determine whether the optical coherent tomography (OCT) or visual filed findings can accelerate the process of demonstrating structural changes caused by exfoliation syndrome for the purpose of early detection of glaucoma damage in order to determine the best method of treatment.

Setting:

Paris

Methods:

Thirty patients with XFS, thirty-one patients with XFG and thirty-one normal subjects were included in the study. All subjects underwent Octopus perimetry and all of them were scanned with Copernicus SD OCT. We used mean defect (MD) and loss variance (LV) as visual field indices and retinal nerve fiber layer (RNFL) and ONH parameters from OCT scans. The results were statistically analysed.

Results:

The exfoliative syndrome (XFS) does not cause any structural changes either in the retina or in the ONH that could be evidenced by SD OCT. Structural changes caused by XFG can be analyzed with OCT. RNFL average thickness in XFG patients was significantly decreased but according to the areas under the ROC curve, all RNFL parameters have a low diagnostic ability. ONH cup was found as parameter from the OCT parameters with best diagnostic ability. But still, MD according to the areas under ROC curve has the best diagnostic ability In XFS and XFG patients.

Conclusions:

It is necessary to regularly monitor patients with XFS, monitor changes in the visual  field regardless of the value of the intraocular  pressure and follow changes in the structure of the optic nerve with OCT. Early changes either of MD,  RNFL average thickness or cupping of the ONH, should be recognized because they suggest the progression from XFS to XFG. The successful long-term management of XFG remains a clinical challenge.

Financial Disclosure:

... receives non-monetary benefits from a competing company

Back to Poster listing